Personalized Anti-Rejection Therapy with Alemtuzumab for Kidney Transplant Recipients

References

• Clayton PA , McDonaldSP , RussGR , ChadbanSJ. Long-term outcomes after acute rejection in kidney transplant recipients: An ANZDATA analysis. J. Am. Soc. Nephrol.30(9), 1697–1707 (2019).
   PubMed Web of Science ®Google Scholar
• Rampersad C , BalshawR , GibsonIWet al. The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am. J. Transplant.22(3), 761–771 (2022).
   PubMed Web of Science ®Google Scholar
• Ho J , OkoliGN , RabbaniRet al. Effectiveness of T cell-mediated rejection therapy: a systematic review and meta-analysis. Am. J. Transplant.22(3), 772–785 (2022).
   PubMed Web of Science ®Google Scholar
• Mayrdorfer M , LiefeldtL , WuKet al. Exploring the complexity of death-censored kidney allograft failure. J. Am. Soc. Nephrol.32(6), 1513–1526 (2021).
   PubMed Web of Science ®Google Scholar
• Loupy A , HaasM , RoufosseCet al. The Banff 2019 Meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am. J. Transplant.20(9), 2318–2331 (2020).
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group . KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant.9(Suppl. 3), S1–S155 (2009).
   PubMed Web of Science ®Google Scholar
• van den Hoogen MW , HoitsmaAJ , HilbrandsLB. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. Expert. Opin. Biol. Ther.12(8), 1031–1042 (2012).
   PubMed Web of Science ®Google Scholar
• van der Zwan M , Clahsen-VanGroningen MC , RoodnatJIet al. The efficacy of rabbit anti-thymocyte globulin for acute kidney transplant rejection in patients using calcineurin inhibitor and mycophenolate mofetil-based immunosuppressive therapy. Ann. Transplant.23, 577–590 (2018).
   PubMed Web of Science ®Google Scholar
• van der Zwan M , BaanCC , van GelderT , HesselinkDA. Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin. Pharmacokinet.57(2), 191–207 (2018).
   PubMed Web of Science ®Google Scholar
• Hanaway MJ , WoodleES , MulgaonkarSet al. ; INTAC Study Group. Alemtuzumab induction in renal transplantation. N. Engl. J. Med.364(20), 1909–1919 (2011).
   PubMed Web of Science ®Google Scholar
• 3C Study Collaborative Group , HaynesR , HardenP , JudgePet al.Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): a randomised trial. Lancet384(9955), 1684–1690 (2014).
   PubMed Web of Science ®Google Scholar
• van den Hoogen MW , HesselinkDA , van SonWJ , WeimarW , HilbrandsLB. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am. J. Transplant.13(1), 192–196 (2013).
   PubMed Web of Science ®Google Scholar
• van der Zwan M , Clahsen-VanGroningen MC , vanden Hoogen MWFet al. Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection. Front. Immunol.11, 1332 (2020).
   PubMed Web of Science ®Google Scholar
• Betjes MGH , KhoMML , LitjensNHR , de WeerdAE , RoodnatJI. Alemtuzumab as second-line treatment for late antibody-mediated rejection of transplanted kidneys. Transplant. Proc.53(7), 2206–2211 (2021).
   PubMed Web of Science ®Google Scholar
• Bouvy AP , KlepperM , BetjesMG , WeimarW , HesselinkDA , BaanCC. Alemtuzumab as antirejection therapy: T cell repopulation and cytokine responsiveness. Transplant. Direct2(6), e83 (2016).
   PubMedGoogle Scholar
• van der Zwan M , LeebeekFWG , SandbergY , KruipMJHA , HesselinkDA. Acquired haemophilia A after alemtuzumab therapy. Haemophilia26(6), e337–e339 (2020).
   PubMed Web of Science ®Google Scholar
• van der Zwan M , HesselinkDA , BrusseEet al. Guillain–Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. Neurol. Neuroimmunol. Neuroinflamm.7(4), e721 (2020).
   PubMed Web of Science ®Google Scholar
• Willicombe M , GoodallD , McLeanAG , TaubeD. Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation. A retrospective study. Transplant. Int.30(11), 1110–1118 (2017).
   PubMed Web of Science ®Google Scholar
• Guthoff M , BergerK , AlthasuKet al. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients. BMC Nephrology21(1), 178 (2020).
   PubMed Web of Science ®Google Scholar
• Hullegie-Peelen DM , vander Zwan M , Clahsen-vanGroningen MCet al. Clinical and molecular profiling to develop a potential prediction model for the response to alemtuzumab therapy for acute kidney transplant rejection. Clin. Pharmacol. Ther.111(5), 1155–1164 (2022).
   PubMed Web of Science ®Google Scholar
• Mengel M , LoupyA , HaasMet al. Banff 2019 Meeting report: molecular diagnostics in solid organ transplantation. Consensus for the Banff human organ transplant (B- HOT) gene panel and open source multicenter validation. Am. J. Transplant.20(9), 2305–2317 (2020).
   PubMed Web of Science ®Google Scholar
• Admiraal R , Jol-vander Zijde CM , FurtadoSilva JMet al. Population pharmacokinetics of alemtuzumab (Campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome. Clin. Pharmacokinet.58(12), 1609–1620 (2019).
   PubMed Web of Science ®Google Scholar
• Meesters-Ensing JJ , AdmiraalR , EbskampLet al. Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept. Front. Pharmacol.13, 828094 (2022).
   PubMed Web of Science ®Google Scholar
• Lin TS , FlinnIW , ModaliRet al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood105(1), 289–291 (2005).
   PubMed Web of Science ®Google Scholar
• Keller CW , RuckT , McHughDet al. Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis. Ann. Clin. Transl. Neurol.6(12), 2586–2594 (2019).
   PubMed Web of Science ®Google Scholar
• Ternant D , BüchlerM , ThibaultGet al. Influence of FcγIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. Pharmacogenet. Genom.24(1), 26–34 (2014).
   PubMed Web of Science ®Google Scholar
• Ternant D , ArnoultC , PugnièreMet al. IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding. J. Immunol.196(2), 607–613 (2016).
   PubMed Web of Science ®Google Scholar
• Loupy A , AubertO , OrandiBJet al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ366, 41923 (2019).
   Google Scholar
• Udomkarnjananun S , TownamchaiN , KerrSJet al. The first Asian kidney transplantation prediction models for long-term patient and allograft survival. Transplantation104(5), 1048–1057 (2020).
   PubMed Web of Science ®Google Scholar
• Kaboré R , HallerMC , HarambatJ , HeinzeG , LeffondréK. risk prediction models for graft failure in kidney transplantation: a systematic review. Nephrol. Dial. Transplant.32(Suppl. 2), ii68–ii76 (2017).
   PubMedGoogle Scholar
• Gonzales MM , BentallA , KremersWK , StegallMD , BorrowsR. Predicting individual renal allograft outcomes using risk models with 1-year surveillance biopsy and alloantibody data. J. Am. Soc. Nephrol.27(10), 3165–3174 (2016).
   PubMed Web of Science ®Google Scholar
• Viglietti D , LoupyA , AubertOet al. Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J. Am. Soc. Nephrol.29(2), 607–619 (2018).
   Web of Science ®Google Scholar
• Rekers NV , de FijterJW , ClaasFHJ , EikmansM. Mechanisms and risk assessment of steroid resistance in acute kidney transplant rejection. Transplant. Immunol.38, 3–14 (2016).
   PubMed Web of Science ®Google Scholar
• Rekers NV , FlaigTM , MallatMJKet al. Donor genotype and intragraft expression of CYP3A5 reflect the response to steroid treatment during acute renal allograft rejection. Transplantation101(9), 2017–2025 (2017).
   PubMed Web of Science ®Google Scholar